InsidersTradesSigma
Track the EDGEWISE THERAPEUTICS INC stock price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €4.6bn. The latest transaction was reported on 13 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: JOANNE DONOVAN. All data is openly available.
Analysts rate EDGEWISE THERAPEUTICS INC Buy (bullish), based on 13 analysts. Average price target: US$51.69.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
EDGEWISE THERAPEUTICS INC es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para enfermedades genéticas raras. Emplea un enfoque innovador para diseñar terapias dirigidas.